UGI Great Debate: Should we use FLOT or CROSS for Neoadjuvant Therapy for Patients with Resectable Gastro-esophageal Junction Adenocarcinomas?
Questions & Discussion
Saturday, March 23, 2024
10:15am – 10:30am ET
Location: C102
Patients with resectable gastroesophageal junction (GEJ) adenocarcinomas are often treated with neoadjuvant therapy. Treatment options include the FLOT chemotherapy regimen and the CROSS chemoradiation regimen. However, there are no guidelines on how to prioritize one over the other. How do we decide which regimen to use for patients with GEJ adenocarcinomas?
